SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending as discussions swirl around potential partnerships with rivals like AMD and Apple for its foundry business, fueled by reports and government initiatives to bolster domestic chip manufacturing. Community members debate the implications of these partnerships, potential for revenue growth, and impact on Intel's valuation, with some expressing optimism about a turnaround driven by government support and AI advancements. Others caution about execution risks and the need for concrete results to justify the stock's recent gains.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is generating buzz as the community rallies to get it trending, emphasizing its active development team and engaged community. Discussions highlight the coin's utilities, ongoing contests, and upcoming staking features, positioning it as more than just another meme coin in the Solana ecosystem. Some users have also expressed excitement for 'Uptober'.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending due to positive sentiment around its potential in the weight loss and diabetes drug market, fueled by a new facility announcement and promising trial data for its oral GLP-1.  The community is actively discussing its competitive positioning against Novo Nordisk and speculating on potential acquisitions in the sector. Some investors are also considering the impact of potential government actions, such as tariffs and direct consumer pricing initiatives.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as chatter revolves around a potential collaboration with Intel as a foundry customer, sparking debate about its impact and the competitive landscape with TSMC and Samsung. Community members are actively discussing the news' validity, potential benefits, and AMD's overall valuation amidst the ever-evolving semiconductor sector. Technical analysis and price target speculation are also contributing to the heightened interest in the stock.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is experiencing volatility, with community discussions focusing on a potential link to ChatGPT's reduced reliance on Reddit data, impacting its AI narrative and prompting a sharp sell-off. Dip buyers are active, while others point to strong institutional ownership and upcoming earnings as reasons for optimism, despite concerns around political bias on the platform. Some traders are also drawing parallels between RDDT and RUM, noting potential political catalysts and high short interest in RUM.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DKNG is trending downwards amidst concerns that prediction markets, like Kalshi and Robinhood, are gaining traction and posing a competitive threat. The community is actively discussing the potential impact on DraftKings' market share and revenue, with some criticizing the company's leadership for not adapting quickly enough. Investors are also monitoring broader industry trends, including regulatory developments and the potential for increased competition.

Rezolve AI Plc operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. It develops AI-based mobile commerce and engagement solutions, simplifying the purchasing process by providing relevant information and facilitating seamless transactions with a single tap. The company enables retailers, brands, and manufacturers to create dynamic connections with consumers across mobile and desktop devices. Rezolve Ai was founded in 2016 and is headquartered in London, the United Kingdom.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI ($RZLV) is trending due to significant volatility following earnings, with community debate centered on the company's future growth and valuation. A short report from Fuzzy Panda is adding to the uncertainty, while bulls point to raised ARR guidance and potential short squeeze setups. The stock's price action and high trading volume are attracting attention as investors digest conflicting viewpoints.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amid social media discussions spurred by Elon Musk's call to cancel subscriptions, citing concerns over content aimed at children and related controversies. The community is debating the impact of these sentiments on the stock's value, while some defend Netflix, pointing to its strong fundamentals and subscriber base. Technical analysis suggests key support and resistance levels are being closely watched as the stock navigates market sentiment.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer ($PFE) is trending as discussions revolve around potential catalysts including a deal with TrumpRx and investment in US manufacturing, which could boost the stock. The community is weighing the impact of these developments on Pfizer's valuation, noting institutional buying and potential for future growth in areas like weight-loss drugs. Some investors believe that the stock is undervalued and anticipate a significant rise.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors digest recent earnings and future guidance, with community members weighing the potential for short-term gains amidst broader discussions of memory market cycles. Despite strong financial results and tailwinds from increased data center spending and AI, some traders are expressing caution, citing overbought conditions and potential pullbacks. Community talking points include discussions around potential squeeze plays, price targets, and the impact of broader market trends.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

U.S. equities gained in Wednesday’s midday trade after opening in the red due to the United States government entering its first shutdown in nearly seven years.Weak jobs data raised the hopes of an interest rate cut later this month, after a report by ADP showed that private payrolls&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/private-payrolls-decline-32000-september/chCYdhBR3ak">declined</a> 32,000 in September, while Wall Street expected an addition of 45,000 jobs during the month. According to the CME FedWatch&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>, the probability of a 25-basis-point rate cut in October has increased to 99%, up&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gold-price-today-record-high-us-government-shutdown/chCY2UvR3a0">from</a> 94.6% on Wednesday.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was up 0.09% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq, rose 0.18%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, edged up by 0.05%.Here are the top stocks making the biggest moves in Wednesday’s midday trade:<a href="https://stocktwits.com/symbol/LAC">Lithium Americas Corp. (LAC)</a>Lithium Americas’ shares were up nearly 27% in Wednesday’s midday trade after the U.S. government&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/retail-buzz-erupts-us-5pct-stake-lithium-americas-government-backed-run/chCotOLR39t">confirmed</a> that it would pick up a 5% stake in the company, along with a 5% stake in the Thacker Pass lithium mine.<a href="https://stocktwits.com/symbol/LAC">LAC stock</a> is up 144% year-to-date.<a href="https://stocktwits.com/symbol/RDDT">Reddit Inc. (RDDT)</a>Reddit shares were down more than 9% after&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://promptwatch.com/data/top-chatgpt-citations-by-domain">data</a> from AI search engine tracker Promptwatch&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/reddit-stock-tumbled-9-percent-today-more-details-inside/chCYEqhR3aN">showed</a> that OpenAI’s ChatGPT cited content from the social media platform in less than 2% of its responses, compared to a peak of 14% in September.<a href="https://stocktwits.com/symbol/RDDT">RDDT stock</a> is up 28% year-to-date.<a href="https://stocktwits.com/symbol/NKE">Nike Inc. (NKE)</a>Nike shares surged by nearly 11% in Wednesday’s midday trade after the company’s first-quarter (Q1) results beat Wall Street expectations. Nike reported earnings per share (EPS) of $0.49 on revenue of $11.72 billion, compared to analyst expectations of an EPS of $0.27 on revenue of $10.99 billion, according to Stocktwits data. Nike’s Q1 performance resulted in a slew of price target hikes from analysts on Wednesday, according to TheFly.<a href="https://stocktwits.com/symbol/NKE">NKE stock</a> is up 7% year-to-date.<a href="https://stocktwits.com/symbol/PLUG">Plug Power Inc. (PLUG)</a>Plug Power shares were up more than 20% in Wednesday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/plug-power-stock-rocketed-14-percent-today-here-is-what-happened/chCYJlYR3aM">announced</a> that it shipped its first 10-megawatt GenEco electrolyzer module to Galp, an energy company based in Portugal. This is the first of 10 planned units, the company stated.<a href="https://stocktwits.com/symbol/PLUG">PLUG stock</a> is up 31% year-to-date.<a href="https://stocktwits.com/symbol/PFE">Pfizer Inc. (PFE)</a>Pfizer shares continued to climb on Wednesday, surging 13% in midday trading and surpassing the nearly 7% surge on Tuesday. President Donald Trump had&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-announces-pfizer-drug-pricing-deal-company-to-invest-70-billion-in-us-manufacturing/chDDgU5R39O">announced</a> that the drugmaker would receive a three-year exemption from national-security-related tariffs. In exchange, the company would have to offer some of its drugs on a new government-run direct-to-consumer website called TrumpRx, as well as make investments in domestic manufacturing.<a href="https://stocktwits.com/symbol/PFE">PFE stock</a> is up 2% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fermi-stock-ipo-debut-on-nasdaq/chCYaR1R3ay">Fermi Stock Makes A Strong Debut On Nasdaq</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Lithium Americas, Reddit, Nike, Plug Power, Pfizer: Stocks Making The Biggest Moves Today

Lithium Americas’ shares were up nearly 27% in Wednesday’s midday trade after the U.S. government confirmed that it would pick up a 5% stake in the company.

Equity

Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?

ALNY's portfolio of rare disease and cardiovascular drugs is boosting revenues and reducing reliance on Amvuttra.

Stock Market News for Oct 1, 2025

Wall Street closed higher on Tuesday, driven by healthcare stocks.

Eli Lilly's stock jumped over 5% on Tuesday after U.S.President Donald Trump unveiled a plan to lower U.S. drug prices, which included a “TrumpRx” direct-to-consumer website and a pricing agreement with Pfizer.&nbsp;Pfizer became the first company to accept the administration’s terms, agreeing to slash drug prices by up to 85% and secure a three-year exemption from pharmaceutical tariffs.BMO Capital Markets analyst Evan Seigerman said the Pfizer deal effectively provided a model for other drugmakers such as Eli Lilly to balance pricing cooperation with policy compliance. He said the structure gave the administration a political win while avoiding the need for harsher price controls or new tariffs, according to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-30/pfizer-to-cut-medicaid-drug-prices-in-deal-with-trump-wapo">report</a>.Cantor analyst Carter Gould said the sharp rally in pharmaceutical shares reflected investor relief that the policy measures were more symbolic than financially disruptive. He noted that Pfizer’s announcement did not change any earnings guidance, suggesting that the market viewed the move as a sign of easing regulatory uncertainty rather than a fundamental earnings risk.The S&amp;P 500 Pharmaceuticals Index rose nearly 4%, while Lilly recorded its best day in more than a month. Pfizer climbed nearly 7%, marking its strongest single-day gain in almost four years.Raymond James health policy analyst Chris Meekins said the TrumpRx program was unlikely to materially affect consumers’ costs unless insurance reforms followed. He said that if the administration’s pricing actions stopped at this stage, it would amount to a win for the pharmaceutical industry, CNN&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edition.cnn.com/2025/09/30/politics/pfizer-drug-prices-trump">noted</a>.Meanwhile, Futurum Equities chief market strategist Shay Baloor&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/StockSavvyShay/status/1973057650150764638">wrote on X</a> that Trump’s agreement with Pfizer to launch TrumpRx, which allows consumers to buy discounted medications directly from manufacturers, could hurt insurers and pharmacy benefit managers.&nbsp;Baloor viewed companies such as Eli Lilly, UnitedHealth, Cigna, and Walgreens as potential losers from the shift, while naming Hims &amp; Hers Health among the likely beneficiaries.Eli Lilly stated that it was in active discussions with the administration to expand patient access, signaling its readiness to participate in broader efforts to increase affordability. The statement followed Trump’s call for drugmakers to align U.S. prices with international levels under his “Most Favored Nation” directive.Commerce Secretary Howard Lutnick said negotiations with major drugmakers were ongoing, while Trump described the plan as a step toward ending what he called global price disparities in medicine.Eli Lilly has not disclosed details of its discussions but said it remains focused on expanding access and improving affordability for patients in the U.S..On Stocktwits, retail sentiment was ‘bullish’ for Eli Lilly and ‘extremely bullish’ for Pfizer, with 24-hour message volumes surging 191% and 780%, respectively.<figure class="image"><img style="aspect-ratio:618/55;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_30_at_10_14_21_PM_png_d8474c8869.webp" alt="Screenshot 2025-09-30 at 10.14.21 PM.png" width="618" height="55"><figcaption>LLY sentiment and message volume as of 10:15 p.m. ET, Sept. 30 | source: Stocktwits</figcaption></figure>One user noted that the new TrumpRx model, which eliminates middlemen, is unlikely to impact margins for companies such as Eli Lilly, Merck, and Pfizer, describing it as a direct-to-consumer shift.&nbsp;<stembedurl>https://stocktwits.com/Jessdog77/message/630503208</stembedurl>Another user described Eli Lilly as a strong performer that continues to show unstoppable momentum.<stembedurl>https://stocktwits.com/Stonkapedia/message/630566985</stembedurl><a href="https://stocktwits.com/symbol/LLY">Eli Lilly’s stock</a> has declined 0.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/nike-retail-investors-turn-more-bullish-as-q1-performance-confirms-turnaround-progress-good-report-in-difficult-market/chCooXAR39N">Nike Retail Investors Turn More Bullish As Q1 Performance Confirms Turnaround Progress: 'Good Report In Difficult Market'</a>

The entrance to the Eli Lilly factory in Kinsale, Co Cork, where weight loss drug Mounjaro is made. Picture date: Sunday May 18, 2025.

Eli Lilly Stock Jumps As Trump’s Drug Price Crackdown Spurs Sector Rally; Analysts Say Pfizer Deal Sets Template For Big Pharma

Analysts said the plan signals a political win that could reshape how major drugmakers engage with U.S. policymakers.

President Donald Trump announced a deal with Pfizer (PFE) on Tuesday that includes steep drug price cuts and&nbsp;a $70 billion investment in domestic manufacturing facilities.Speaking at the White House, Trump said Pfizer has agreed to provide some of its most widely used medications “at heavily discounted prices of anywhere between 50 and even 100%.” He stated that the drugs will be made available for direct purchase online through a government-operated website called&nbsp;‘TrumpRX.’ It would allow people to pay cash for certain drugs directly from the website, at a discounted price negotiated by the government.<a href="http://stocktwits.com/symbol/PFE">Pfizer’s stock</a> was up 5.5% in midday trade. On Stocktwits, retail sentiment around the stock rose to ‘extremely bullish’ from ‘bullish’ as chatter increased to ‘high’ from ‘normal’ levels over the past day. The stock was also among the top trending tickers on the platform at the time of writing.&nbsp;Trump added that all new medications introduced by Pfizer in the U.S. market will be sold at “most favored patient costs,” a reference to his administration’s push to tie domestic prices to the lowest rates paid abroad.In addition to price reductions, Trump said Pfizer will commit $70 billion to expand and restore pharmaceutical manufacturing facilities in the United States. “They’re going to bring a lot of their facilities to make their drugs … right here in America,” Trump said, adding that the investment will also fund research and development.“With this deal we’ve signed today, we have satisfied all four of the President’s requirements,” said Albert Bourla, CEO of Pfizer. “The President is absolutely right—tariffs are the most powerful tool to motivate behavior, and they clearly motivated ours.” He stated the company has secured a three-year grace period from President Donald Trump’s promised tariffs on pharmaceuticals in a deal that would lower some of its U.S. drug prices.Trump indicated that more pharmaceutical deals are in progress. He also threatened that if other pharmaceutical companies don’t lower their prices, they could be subject to an extra tariff of between 5% to 8%.&nbsp;This comes after the President said last week that his administration would impose 100% tariffs on branded or patented drugs unless manufacturers begin building U.S.-based production plants by Oct. 1, 2025.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-pulls-back-to-112-k-ahead-of-potential-us-government-shutdown/chDDEngR3BK">Bitcoin Pulls Back To $112K Ahead Of Potential US Government Shutdown</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump announces a deal with Pfizer to lower Medicaid drug prices in the Oval Office of the White House on September 30, 2025 in Washington, DC. (Photo by Win McNamee/Getty Images)

Trump Announces Pfizer Drug-Pricing Deal, Company To Invest $70 Billion in US Manufacturing

The President stated that the drugs will be made available for direct purchase online through a government-operated website called TrumpRX.

President Donald Trump is reportedly set to announce a drug-pricing deal with Pfizer (PFE) later on Tuesday.&nbsp;According to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.washingtonpost.com/politics/2025/09/30/drug-prices-pfizer/">report</a> by The Washington Post, citing sources familiar with the matter, the deal would&nbsp;require Pfizer&nbsp;to voluntarily offer its medications through Medicaid at reduced prices. The announcement comes amid the White House’s broader push for “Most Favored Nation” pricing deals, which aim to tie U.S. drug costs to the lowest prices paid by wealthy countries.<a href="http://stocktwits.com/symbol/PFE">Pfizer’s stock</a> rose&nbsp;more than 4% in morning trade with retail sentiment on Stocktwits trending in ‘bullish’ territory over the past day.&nbsp;It was also among the top trending tickers on the platform at the time of writing.The deal follows the May executive order outlining the Trump administration’s effort to secure voluntary price reductions from pharmaceutical manufacturers. The deadline for those agreements was Monday, and officials have been negotiating with companies to bring them on board.The pharmaceutical industry has sought to soften the impact of Trump’s demands through concessions. The Pharmaceutical Research and Manufacturers of America on Monday announced voluntary measures to support the administration’s goals, including a website designed to help Americans compare lower-priced drugs.Trump has long argued that U.S. drug spending is excessive and pursued similar pricing initiatives during his first term. Last week, he also announced new tariffs on pharmaceuticals, heavy trucks, and furniture, including a 100% duty on patented drugs unless the producer is building a U.S. manufacturing facility.“Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America,” Trump&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/posts/115267512131958759">posted</a> on social media Thursday. “There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started.”Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-pulls-back-to-112-k-ahead-of-potential-us-government-shutdown/chDDEngR3BK">Bitcoin Pulls Back To $112K Ahead Of Potential US Government Shutdown</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Optimism has also been recently driven by Pfizer’s solid quarterly performance.

Trump To Announce Drug-Pricing Pact With Pfizer Later Today: Report

According to a report by The Washington Post, the deal would require Pfizer to voluntarily offer its medications through Medicaid at reduced prices. 

Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit

Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.     

AZN, Daiichi's Enhertu sBLA Gets FDA Priority Review for Breast Cancer

AstraZeneca and Daiichi's Enhertu wins FDA priority review in breast cancer, backed by phase III data showing a 44% lower progression risk.

Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?

VKTX faces rising pressure in the obesity drug race as Pfizer re-enters with a $4.9B Metsera deal and rivals scale up.

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Current Price	$27.29
Prev Close	$25.48
Open	$25.97
Dividend Yield	6.37%
50-Day Moving Average	$24.56
Beta	0.44
Avg. Volume	43.39M
PE Ratio	13.55

52-Week High	$30.43
52-Week Low	$20.92
Market Capitalization	$144.87B
EPS (Annual)	$1.41
Price to Book	1.63
Revenue Per Employee	$785,518.52
Enterprise Value/EBITDA	N/A

PFE
Pfizer Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PFE News

PFE Pfizer Inc